Sarah Bacus

6.8k citations

68 papers · 5.4k indexed · 1 hit paper · h-index 39

Impact in

Oncology top 0.5%
- HER2/EGFR in Cancer Research
- Cancer-related Molecular Pathways
- Cancer Treatment and Pharmacology
Radiology, Nuclear Medicine and Imaging top 0.5%
- Monoclonal and Polyclonal Antibodies Research

Papers in

Oncology 54
- HER2/EGFR in Cancer Research 39
- Cancer-related Molecular Pathways 8
- Cancer Treatment and Pharmacology 8
Radiology, Nuclear Medicine and Imaging 24
- Monoclonal and Polyclonal Antibodies Research 22

Co-authors: Yosef Yarden Ljuba Lyass Neil L. Spector Elior Peles Raymond A. Koski Duanzhi Wen Hsieng S. Lu Wenle Xia
Journals: Journal of Clinical Oncology (8 papers)Molecular Cancer Therapeutics (5 papers)Oncogene (5 papers)Journal of Biological Chemistry (4 papers)Cancer Research (4 papers)
Partner nations: United States Israel United Kingdom

In The Last Decade

Sarah Bacus

68 papers receiving 5.3k citations

Hit Papers

align trajectories log scale

Neu differentiation factor: A transmembrane glycoprotein containing an EGF domain and an immunoglobulin homology unit 1992 · 504 citations

Peers

Countries citing papers authored by Sarah Bacus

Since Specialization

Citations

This map shows the geographic impact of Sarah Bacus's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sarah Bacus with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sarah Bacus more than expected).

Fields of papers citing papers by Sarah Bacus

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sarah Bacus. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sarah Bacus. The network helps show where Sarah Bacus may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Sarah Bacus, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Sarah Bacus Line = papers co-authored together Sarah Bacus links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Cytoplasmic Cyclin E Predicts Recurrence in Patients with Breast Cancer Clinical Cancer Research ·Kelly K. Hunt, Cansu Karakaş, Min Jin Ha, Anna Biernacka, Min Yi, Ayşegül A. Şahin, H I Supriyadi, Gabriel N. Hortobágyi, Melissa L. Bondy, Patricia A. Thompson, Kwok‐Leung Cheung, Ian O. Ellis, Sarah Bacus, W. Fraser Symmans, Kim‐Anh Do, Khandan Keyomarsi	2016	49
2	Genomic and Immunological Tumor Profiling Identifies Targetable Pathways and Extensive CD8+/PDL1+ Immune Infiltration in Inflammatory Breast Cancer Tumors Molecular Cancer Therapeutics ·Christopher A. Hamm, Diarmuid Moran, Michel Lejeune, Patricia B. Trusk, Karen Pry, Mark Sausen, Siân Jones, Victor E. Velculescu, Massimo Cristofanilli, Sarah Bacus	2016	44
3	Lapatinib Plasma and Tumor Concentrations and Effects on HER Receptor Phosphorylation in Tumor PLoS ONE ·Neil L. Spector, Faith C. Robertson, Sarah Bacus, Kimberly Blackwell, Deborah A. Smith, Kelli Glenn, Leanne Cartee, Jennifer L. Harris, Mendalka, Marshall McDonald, Eli Avisar, Peter D. Beitsch, Kevin M. Koch	2015	21
4	KRAS Mutation Status Is Associated with Enhanced Dependency on Folate Metabolism Pathways in Non–Small Cell Lung Cancer Cells Molecular Cancer Therapeutics ·Diarmuid Moran, Patricia B. Trusk, Karen Pry, Keren Paz, David Sidransky, Sarah Bacus	2014	55
5	An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models Breast Cancer Research ·Wenle Xia, T. G. Rankine, Sumin Zhao, Lei-Hua Liu, Takuya Osada, Qing Cheng, Julia Wulfkuhle, William R. Gwin, Xiaoyi Yang, Rosa I. Gallagher, Sarah Bacus, H. Kim Lyerly, Neil L. Spector	2013	113
6	Phase II Trial of Dasatinib in Patients with Metastatic Breast Cancer Using Real-Time Pharmacodynamic Tissue Biomarkers of Src Inhibition to Escalate Dosing Clinical Cancer Research ·Christina I. Herold, Vijaya Chadaram, Bercedis L. Peterson, P. Kelly Marcom, Judith O. Hopkins, Gretchen Kimmick, Justin Favaro, Erika Hamilton, John W. Dickson, Sarah Bacus, Kimberly Blackwell	2011	64
7	A recombinant decoy comprising EGFR and ErbB-4 inhibits tumor growth and metastasis Oncogene ·Moshit Lindzen, Sílvia Carvalho, Alex Starr, Nir Ben‐Chetrit, Yahya Saputra, Wolfgang J. Köstler, A. Rabinkov, Sara Lavi, Sarah Bacus, Yosef Yarden	2011	25
8	Phase II, Randomized Trial to Compare Anastrozole Combined with Gefitinib or Placebo in Postmenopausal Women with Hormone Receptor–Positive Metastatic Breast Cancer Clinical Cancer Research ·Massimo Cristofanilli, Vicente Valero, Aroop Mangalik, Melanie Royce, Ian Rabinowitz, Francis P. Arena, Joan F. Kroener, V. Kulinkovich, Claire Watkins, Sarah Bacus, Elsa M. Cora, Elizabeth J. Anderson, Patrick Magill	2010	134
9	Activation of AMP-activated protein kinase by human EGF receptor 2/EGF receptor tyrosine kinase inhibitor protects cardiac cells Proceedings of the National Academy of Sciences ·Neil L. Spector, Yosef Yarden, Bradley L. Smith, Ljuba Lyass, Patricia B. Trusk, Karen Pry, Jason E. Hill, Wenle Xia, Rony Seger, Sarah Bacus	2007	89
10	Regulation of Survivin by ErbB2 Signaling: Therapeutic Implications for ErbB2-Overexpressing Breast Cancers Cancer Research ·Wenle Xia, John Bisi, Jay C. Strum, Lei-Hua Liu, Kevin Carrick, De Hui Zhang, Amanda L. Treece, Mary Ann Hardwicke, Michael Dush, J. Chamero, Ron E. Westlund, Sumin Zhao, Sarah Bacus, Neil L. Spector	2006	128
11	Study of the Biologic Effects of Lapatinib, a Reversible Inhibitor of ErbB1 and ErbB2 Tyrosine Kinases, on Tumor Growth and Survival Pathways in Patients With Advanced Malignancies Journal of Clinical Oncology ·Neil L. Spector, Wenle Xia, Howard A. Burris, Herbert I. Hurwitz, E. Claire Dees, Afshin Dowlati, Bert H. O’Neil, Beth Overmoyer, P. Kelly Marcom, Kimberly Blackwell, Deborah A. Smith, Kevin M. Koch, Andrew G. Stead, Seco Martínez, Matthew J. Ellis, Lei-Hua Liu, Olson Ap, Troy Bremer, Jennifer L. Harris, Sarah Bacus	2005	290
12	The efficacy of Herceptin therapies is influenced by the expression of other erbB receptors, their ligands and the activation of downstream signalling proteins British Journal of Cancer ·Bradley L. Smith, D Chin, Warren Maltzman, Katherine Crosby, Gabriel N. Hortobágyi, Sarah Bacus	2004	69
13	Epigen, the Last Ligand of ErbB Receptors, Reveals Intricate Relationships between Affinity and Mitogenicity Journal of Biological Chemistry ·Bose Kochupurakkal, Daniel Harari, Yosephine Angelia Hutapea, Galia Maik-Rachline, Ljuba Lyass, Gal Gur, Oluwashanu Balogun, Ami Citri, Sara Lavi, Raya Eilam, Vered Chalifa‐Caspi, Zelig Eshhar, Eli Pikarsky, Ronit Pinkas‐Kramarski, Sarah Bacus, Yosef Yarden	2004	76
14	Role of epidermal growth factor receptor family members in growth and differentiation of breast carcinoma. PubMed ·Николин Елез-Бурњаковић, Nishta Rao, Sarah Bacus, Jiang Jiaming, 阿部春樹, Ingegerd Hellström, Padmavathi Pannuru, Michael Rudoni	1998	36
15	The oncogenic ErbB-2/ErbB-3 heterodimer is a surrogate receptor of the epidermal growth factor and betacellulin Oncogene ·Ronit Pinkas‐Kramarski, Anne E.G. Lenferink, Sarah Bacus, Ljuba Lyass, Schüter Systems, Leah N. Klapper, Eldad Tzahar, Michael Sela, Giamarco Dariva, Yosef Yarden	1998	75
16	ErbB Tyrosine Kinases and the Two Neuregulin Families Constitute a Ligand-Receptor Network Molecular and Cellular Biology ·Ronit Pinkas‐Kramarski, Maya Shelly, A. Siedow, Sarah Omberg, Ljuba Lyass, Iris Alroy, Mahmoud Mohammed mahmoud Nasef, Angera H. Kuo, James D. Moyer, Sara Lavi, Miriam Eisenstein, Barry Ratzkin, Rony Seger, Sarah Bacus, Jacalyn H. Pierce, Glenn C. Andrews, Yosef Yarden	1998	113
17	Type 1 receptor tyrosine kinases are differentially phosphorylated in mammary carcinoma and differentially associated with steroid receptors. PubMed ·Sarah Bacus, D Chin, Yosef Yarden, C R Zelnick, David F. Stern	1996	77
18	Neu differentiation factor (Heregulin) activates a p53-dependent pathway in cancer cells. PubMed ·Sarah Bacus, Yosef Yarden, Moshe Oren, D Chin, Ljuba Lyass, C R Zelnick, Alexander R. Kazarov, Wendy M. Toyofuku, Amani Abdul Rahman Makawi Abdul Rahman, Roger R. Beerli, Nancy E. Hynes, Shuhei Tonomura, Rebecca Haffner, Andrei V. Gudkov, Khandan Keyomarsi	1996	50
19	Neu differentiation factor: A transmembrane glycoprotein containing an EGF domain and an immunoglobulin homology unit Cell ·Duanzhi Wen, Elior Peles, Rod Cupples, Sidney V. Suggs, Sarah Bacus, Yi Luo, С.П. Ломов, Sylvia Hu, Hilal Dudu, Jie-Feng Liu, Raymond A. Koski, Hsieng S. Lu, Yosef Yarden Hit paper breakdown →	1992	504
20	Isolation of the NeuHER-2 stimulatory ligand: A 44 kd glycoprotein that induces differentiation of mammary tumor cells Cell ·Elior Peles, Sarah Bacus, Raymond A. Koski, Hsieng S. Lu, Duanzhi Wen, Steven G. Ogden, Jie-Feng Liu, Yosef Yarden	1992	453

About Sarah Bacus

Sarah Bacus is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging, Genetics, Cancer Research and Molecular Biology, having authored 68 papers that have together received 5.4k indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (39 papers), Monoclonal and Polyclonal Antibodies Research (22 papers), Chronic Lymphocytic Leukemia Research (10 papers), Lung Cancer Treatments and Mutations (10 papers), Glycosylation and Glycoproteins Research (9 papers), Cancer-related Molecular Pathways (8 papers), Cancer Treatment and Pharmacology (8 papers) and PI3K/AKT/mTOR signaling in cancer (5 papers). The work is most often cited by research in Oncology (3.5k citations), Radiology, Nuclear Medicine and Imaging (1.5k citations), Immunology and Allergy (288 citations), Cancer Research (662 citations) and Molecular Biology (2.8k citations). Sarah Bacus has collaborated with scholars based in United States, Israel and United Kingdom. Frequent co-authors include Yosef Yarden, Ljuba Lyass, Neil L. Spector, Elior Peles, Raymond A. Koski, Duanzhi Wen, Hsieng S. Lu, Wenle Xia, Patricia B. Trusk and D Chin. Their work appears in journals such as Journal of Clinical Oncology, Molecular Cancer Therapeutics, Oncogene, Journal of Biological Chemistry and Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact